1
|
Tao Q, Xiao G, Wang T, Zhang L, Yu M, Peng L, Han L, Du X, Han W, He S, Lyu M, Zhu Y. Identification of linoleic acid as an antithrombotic component of Wenxin Keli via selective inhibition of p-selectin-mediated platelet activation. Biomed Pharmacother 2022; 153:113453. [DOI: 10.1016/j.biopha.2022.113453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Revised: 07/10/2022] [Accepted: 07/18/2022] [Indexed: 11/27/2022] Open
|
2
|
Wan S, Cui S, Jiang M, Wu Q, Ji Y, Xu Y, Gong G. Dual-target synergistic antithrombotic mechanism of a Dabigatran etexilate analogue (HY023016). Clin Exp Pharmacol Physiol 2022; 49:567-576. [PMID: 35147244 DOI: 10.1111/1440-1681.13634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2021] [Revised: 12/26/2021] [Accepted: 01/24/2022] [Indexed: 11/30/2022]
Abstract
Thrombin has long been considered a desirable antithrombotic target, but anti-thrombin therapy without anti-platelet therapy has never achieved the ideal effect. HY023016, derived from dabigatran etexilate, exhibited a potent antithrombotic efficacy. In the present study, mechanisms underlying this effect were explored. HY023016 strongly decreased the binding of thrombin to recombinant GPIbα N-terminal sequence which was confirmed by surface plasmon resonance. Flow cytometry revealed that HY023016 selectively decreased the binding of antibody to GPIbα and inhibited the washed human platelet aggregation induced by thrombin. Fluorescence experiment showed that HY023016 remarkably inhibited exosite II by a loss of affinity for the γ'-peptide of fibrinogen. Using intravital microscopy, we observed and recorded the dynamic process of thrombus formation and found that HY023016 effectively prevented thrombus formation in rat arteriovenous shunt thrombosis model. On the basis of these findings, we propose that HY023016 provides a novel insight into the antithrombotic mechanism, which exerts synergistic anticoagulant and antiplatelet effects through thrombin and GPIbα.
Collapse
Affiliation(s)
- Sheng Wan
- Department of Pharmacology, China Pharmaceutical University, Nanjing, 211198, China
| | - Shuang Cui
- Department of Pharmacology, China Pharmaceutical University, Nanjing, 211198, China.,State Key Laboratory of Natural Medicines, Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Tongjiaxiang 24, Nanjing, 21009, China
| | - Minrui Jiang
- Department of Pharmacology, China Pharmaceutical University, Nanjing, 211198, China
| | - Qian Wu
- Department of Pharmacology, China Pharmaceutical University, Nanjing, 211198, China
| | - Yingying Ji
- Department of Pharmacology, China Pharmaceutical University, Nanjing, 211198, China
| | - Yungen Xu
- Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, China
| | - Guoqing Gong
- Department of Pharmacology, China Pharmaceutical University, Nanjing, 211198, China
| |
Collapse
|
3
|
Zhang H, Chen H, Wu X, Sun T, Fan M, Tong H, Zhu Y, Yin Z, Sun W, Zhang C, Zheng X, Chen X. Tetramethylpyrazine alleviates diabetes-induced high platelet response and endothelial adhesion via inhibiting NLRP3 inflammasome activation. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2022; 96:153860. [PMID: 34836743 DOI: 10.1016/j.phymed.2021.153860] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 11/01/2021] [Accepted: 11/14/2021] [Indexed: 06/13/2023]
Abstract
BACKGROUND The inflammatory state of diabetes promotes high platelet response and endothelial adhesion, which are the main risk factors for cardiovascular events. Tetramethylpyrazine (TMP) is an amide alkaloid isolated from the traditional Chinese medicine Rhizoma Ligustici Chuanxiong, which has been widely used in the clinical treatment of ischemic cardiovascular disease. PURPOSE This study aimed to investigate whether TMP could alleviate diabetes-induced high platelet response and endothelial adhesion and the underlying mechanisms. METHODS Type 2 diabetes mellitus (T2DM) rat model was established by high-fat feeding combined with low dose of streptozotocin. Rats in the TMP treatment group were administered with TMP (100 or 200 mg/kg) for 21 days. Cultured human umbilical vein endothelial cells (HUVECs) were stimulated with glucose (5.5 mM) to induce endothelial activation. The NOD-like receptor protein 3 (NLRP3) over- and low-expressing cell models were established via transfection of NLRP3 lentivirus plasmid into HUVECs. INF39 (25 mg/kg), a chemical inhibitor of NLRP3 inflammasome, was used to explore the role of NLRP3 in T2DM associated high platelet response and endothelial adhesion. RESULTS TMP effectively improved the prothrombotic phenotypes and inhibited the expression of vascular inflammatory factors and adhesion molecules in T2DM rats. TMP inhibited NLRP3 inflammasome and reduced the adhesion of HUVECs to platelets and monocytes in vitro. Over-expression of NLRP3 blocked the effect of TMP on HUVECs activation and adhesion, while TMP had no effect on NLRP3 low-expressing HUVECs. The NLRP3 inhibitor INF39 produced similar effects of TMP on diabetes-induced high platelet response, endothelial adhesion and vascular inflammation. CONCLUSION TMP ameliorates diabetes-induced high platelet response and endothelial adhesion via inhibiting NLRP3 inflammasome activation in T2DM rats, which provide a new basis for the clinical prevention and treatment of diabetes-associated cardiovascular events.
Collapse
Affiliation(s)
- Haowen Zhang
- College of Health Preservation and Rehabilitation, Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China; Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, QinHuai District, Nanjing 210029, China
| | - Hanyu Chen
- School of Rehabilitation Science, Nanjing Normal University of Special Education, Nanjing 210038, China
| | - Xiang Wu
- Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, QinHuai District, Nanjing 210029, China
| | - Tong Sun
- Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, QinHuai District, Nanjing 210029, China
| | - Manlu Fan
- Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, QinHuai District, Nanjing 210029, China
| | - Huaqin Tong
- Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, QinHuai District, Nanjing 210029, China
| | - Yejin Zhu
- School of Medicine • Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China
| | - Zhe Yin
- State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 24 Tongjiaxiang, Gulou District, Nanjing 210009, China
| | - Weixin Sun
- Department of Cardiology, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Yancheng 224000, China
| | - Chao Zhang
- School of Medicine • Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China
| | - Xiao Zheng
- State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 24 Tongjiaxiang, Gulou District, Nanjing 210009, China.
| | - Xiaohu Chen
- Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, QinHuai District, Nanjing 210029, China.
| |
Collapse
|
4
|
Chen X, Zhu W, Liu H, Deng F, Wang W, Qin L. Preparation of injectable clopidogrel loaded submicron emulsion for enhancing physicochemical stability and anti-thrombotic efficacy. Int J Pharm 2022; 611:121323. [PMID: 34848363 DOI: 10.1016/j.ijpharm.2021.121323] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 11/11/2021] [Accepted: 11/24/2021] [Indexed: 01/13/2023]
Abstract
Due to the superior safety and therapeutic efficacy, clopidogrel (CLP) has been widely used to prevent postoperative thrombosis. However, limitations of delayed absorption and metabolic activation of clopidogrel after oral administration hinder its clinic use for acute thrombosis treatment in percutaneous coronary intervention (PCI). Although clopidogrel aqueous injection systems were designed and developed, chemical instability under physiological condition or vascular irritation remains to be solved. In this study, we aim to prepare an injectable clopidogrel loaded submicron emulsion to overcome the drawbacks of conventional clopidogrel aqueous formulation and improve the antiplatelet aggregation effects. Results showed that this delivery system exerted inspiring features including uniform particle size, higher drug loading capacity and sustained drug release behavior. It can dramatically upgrade the formulation stability and prevent the drug degradation under sterilization or higher pH environments. No remarkable droplet size increase or drug content decrease was observed during storage. Compared to CLP tablet, the peak drug concentration (Cmax) and area under the curve (AUC) of CLP emulsion increased by 12.01-fold and 4.69-fold, respectively. Most importantly, it exerted excellent in vivo anti-thrombotic effect on numerous designed animal models. Conclusively, submicron emulsion is a promising delivery system for improving clopidogrel stability and anti-thrombotic efficacy.
Collapse
Affiliation(s)
- Xuehong Chen
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China; The Information Area of Xihu Industrial Base Shilong Town, Dongguan 523000, China
| | - Wanye Zhu
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Huan Liu
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Fengjian Deng
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Wanting Wang
- HEC Industrial Development Co. Changan Town, Dongguan 523000, China.
| | - Linghao Qin
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
| |
Collapse
|
5
|
The role of Sphingomyelin synthase 2 (SMS2) in platelet activation and its clinical significance. Thromb J 2021; 19:27. [PMID: 33910580 PMCID: PMC8082820 DOI: 10.1186/s12959-021-00282-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Accepted: 04/15/2021] [Indexed: 12/18/2022] Open
Abstract
Background Sphingomyelin (SM) is an essential component of biological lipid rafts, and it plays an indispensable role in maintaining plasma membrane stability and in mediating signal transduction. The ultimate biosynthesis of SM is catalyzed by two sphingomyelin synthases (SMSs) namely SMS1 and SMS2, which are selectively distributed in the trans-Golgi apparatus and the plasma membrane. It has been demonstrated that SMS2 acts as an irreplaceable molecule in the regulation of transmembrane signaling, and loss of SMS2 has been reported to worsen atherosclerosis and liver steatosis. However, the function of SMS2 in platelet activation and its association with the pathological process of thrombosis in acute coronary syndrome (ACS) and portal hypertension (PH) remain unclear. Methods In this study, we tested the role of SMS2 in platelet activation and thrombosis using SMS2 knockout (SMS2 –/–) mice and SMS2-specific inhibitor, D609. Furthermore, we detected SMS2 expression in patients with ACS and PH. Results SMS2 –/– platelets showed significant reduction in platelet aggregation, spreading, clot retraction and in vivo thrombosis. Similar inhibitory effects on platelet activation were detected in D609-treated wild-type platelets. PLCγ/PI3K/Akt signaling pathway was inhibited in SMS2 –/– platelets and D609-treated wild-type platelets. In addition, we discovered that platelet SMS2 expression was remarkably increased in patients with ACS and PH, compared with healthy subjects. Conclusions Our study indicates that SMS2 acts as a positive regulator of platelet activation and thrombosis, and provides a theoretical basis for the potential use of D609 in anti-thrombosis treatment. Supplementary Information The online version contains supplementary material available at 10.1186/s12959-021-00282-x.
Collapse
|
6
|
Chen Q, Yang H, Li Y, Wang X, Wei L, Du Y. Effects of Yak skin gelatin on platelet activation. Food Funct 2019; 10:3379-3385. [PMID: 31107473 DOI: 10.1039/c8fo02513d] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Studies have shown that gelatin is not only a good hemostatic material, but also a food additive with potentially broad use. Yak skin gelatin is a new gelatin resource, but its oral coagulant effects have not been studied. Given the central role of platelets in hemostasis, in this study we examined the pharmacodynamical differences between different molecular Yak skin gelatins on platelet activation. The hemostatic effects of Yak skin gelatins with different molecular weight distributions were evaluated for bleeding time (BT), clotting time (CT), and platelet activity by measuring the contents of P-selectin, platelet membrane glycoprotein Ia/IIa (GP Ia/IIa), platelet membrane glycoprotein IIb/IIIa (GP IIb/IIIa), and platelet membrane glycoprotein IV (GP IV). Intragastric administration of Yak skin gelatin resulted in a significant reduction in CT and BT, and an increase in the contents of P-selectin, GP Ia/IIa, GP IIb/IIIa, and GP IV in all groups in comparison with the control group. The strongest activation of platelets by Yak skin gelatin was observed with size between 0.1 μm and 0.22 μm, and activation may have been in response to improving GP IIb/IIIa and GP IV levels. When measuring the levels of an established indicator of platelet activation, platelet activation-dependent granule membrane protein (CD62P), its promotion was observed for all molecular weight ranges of Yak skin gelatins. In brief, Yak skin gelatin has hemostatic effects, and Yak skin gelatin fractions between 0.1 μm and 0.22 μm are the primary effectors of hemostasis via promoting platelet membrane glycoprotein activities and strengthening platelet function.
Collapse
Affiliation(s)
- Qi Chen
- Qinghai Key Laboratory of Tibetan Medicine Pharmacology and Safety Evaluation, Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Chinese Academy of Sciences, 810008 Xining, China.
| | | | | | | | | | | |
Collapse
|
7
|
Liu J, Xu D, Xia N, Hou K, Chen S, Wang Y, Li Y. Anticoagulant Activities of Indobufen, an Antiplatelet Drug. Molecules 2018; 23:molecules23061452. [PMID: 29914049 PMCID: PMC6099839 DOI: 10.3390/molecules23061452] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Revised: 06/09/2018] [Accepted: 06/12/2018] [Indexed: 01/08/2023] Open
Abstract
Indobufen is a new generation of anti-platelet aggregation drug, but studies were not sufficient on its anticoagulant effects. In the present study, the anticoagulant activity of indobufen was determined by monitoring the activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) in rabbit plasma. We evaluated the anticoagulant mechanisms on the content of the platelet factor 3,4 (PF3,4), and the coagulation factor 1, 2, 5, 8, 10 (FI, II, V, VIII, X) in rabbits, as well as the in vivo bleeding time and clotting time in mice. The pharmacodynamic differences between indobufen and warfarin sodium, rivaroxaban, and dabigatran were further studied on thrombus formation and the content of FII and FX in rats. Animal experiments showed that intragastric-administrated indobufen can significantly reduce the APTT, PT, TT, PF3, FI, II, V, VIII, and X plasma contents. Its inhibitory effect on plasma FII was better than thrombin inhibitor dabigatran with effect on FX better than FXa inhibitor rivaroxaban. These results suggest that indobufen has some anticoagulant effects as strong as some conventional anticoagulants. The mechanism may be related to both exogenous and endogenous coagulation system.
Collapse
Affiliation(s)
- Jia Liu
- Department of Marketing, Hangzhou Zhongmei Huadong Pharmaceutical Company, Hangzhou 310011, China.
| | - Dan Xu
- State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing 210009, China.
| | - Nian Xia
- State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing 210009, China.
| | - Kai Hou
- State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing 210009, China.
| | - Shijie Chen
- State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing 210009, China.
| | - Yu Wang
- Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Department of Pharmacology, Nanjing Medical University, 140 Hanzhong Road, Nanjing 210029, China.
| | - Yunman Li
- State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing 210009, China.
| |
Collapse
|
8
|
The Effects of Bairesi Complex Prescription (a Uyghur Medicine Prescription) and Its Five Crude Herbal Extracts on Melanogenesis in G-361 Cells. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2016; 2016:8415359. [PMID: 27069495 PMCID: PMC4812344 DOI: 10.1155/2016/8415359] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/10/2015] [Revised: 01/19/2016] [Accepted: 01/20/2016] [Indexed: 11/17/2022]
Abstract
Vitiligo is considered a preimmune stage of a disease that is not well clarified. This condition is difficult to treat because there is no definite cure. Uyghur medicine is an important part of traditional Chinese medicine. There are many types of prescriptions that are used for the treatment of vitiligo. Bairesi complex prescription is one of the active prescriptions for vitiligo that is used in the clinic. However, the intensities of melanogenesis due to uses of Bairesi complex prescription and its five constituent crude herbs have not been reported yet. In the present study, we found that the hot water extracts of Bairesi complex prescription and the crude herbs were more effective in eliciting melanin production in G-361 cells than the EtOH extracts. Furthermore, the Bairesi complex prescription exhibited less cytotoxicity and was more effective in melanin formation than the five crude herbal extracts. In the present study, we also discuss the mechanisms of melanogenesis due to the use of the Bairesi complex prescription and its single crude herbal extracts.
Collapse
|
9
|
Cheng J, Ma T, Liu W, Wang H, Jiang J, Wei Y, Tian H, Zou N, Zhu Y, Shi H, Cheng X, Wang C. In in vivo evaluation of the anti-inflammatory and analgesic activities of compound Muniziqi granule in experimental animal models. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE 2016; 16:20. [PMID: 26800679 PMCID: PMC4722770 DOI: 10.1186/s12906-016-0999-y] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Accepted: 01/12/2016] [Indexed: 11/20/2022]
Abstract
BACKGROUND Compound Muniziqi granule (MNZQ), a traditional Uighur medicinal preparation, comprises 13 species of medicinal plants. MNZQ is traditionally used for regulating body immunity, modulating inflammation and pain, detoxification, and inhibiting tumor growth. This study aims to scientifically evaluate the anti-inflammatory and analgesic activities of MNZQ, support its clinical use and further research with scientific evidence. METHODS The analgesic activity of MNZQ was evaluated using hot plate test and acetic acid-induced abdominal writhing test. Acute inflammation was evaluated using xylene-induced ear edema and carrageenan-induced paw edema models, while chronic inflammation was evaluated using cotton pellet-induced granuloma model. RESULTS MNZQ exerted analgesic activities with a significant dose-dependent increase in latency in the hot plate test. The percentage inhibition suggested that MNZQ exhibited analgesic activities in the central nervous system. Meanwhile, MNZQ at 0.8, 2.4, and 7.2 g/kg strongly inhibited the acetic acid-induced writhing response by 25.22% (p < 0.01), 44.60% (p < 0.001), and 49.41% (p < 0.001), respectively. MNZQ also exerted analgesic activities in the peripheral nervous system. Moreover, MNZQ was demonstrated a significant anti-inflammatory effect against xylene-induced edema in a dose-dependent manner. The percentage inhibition was 22.24% (p < 0.01) at the highest dosage of 7.2 g/kg. MNZQ at 1.62 and 4.86 g/kg significantly reduced carrageenan-induced rat hind paw edema by 82.43% and 84.32% (p < 0.001), respectively, 1 h after injecting carrageenan, and the inhibitory effect lasted for 5 h. MNZQ also exerted a significant anti-inflammatory effect against cotton pellet-induced granuloma formation. MNZQ at 1.62 and 4.86 g/kg could inhibit granuloma formation by 17.07% and 17.60%, respectively, whereas the percentage inhibition of diclofenac was 33.12%. CONCLUSIONS The results obtained suggest that MNZQ possesses potential anti-inflammatory and analgesic activities. This study provides a scientific basis for the use of MNZQ in alleviating pain and treating inflammatory disorders.
Collapse
Affiliation(s)
- Juanjuan Cheng
- Institute of Chinese Materia Medica, The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai,, 201203, China
| | - Tingyun Ma
- Institute of Chinese Materia Medica, The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai,, 201203, China
| | - Wei Liu
- Institute of Chinese Materia Medica, The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai,, 201203, China
| | - Hanxue Wang
- Institute of Chinese Materia Medica, The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai,, 201203, China
| | - Jizong Jiang
- Institute of Chinese Materia Medica, The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai,, 201203, China
| | - Yue Wei
- Institute of Chinese Materia Medica, The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai,, 201203, China
| | - Hemiao Tian
- Institute of Chinese Materia Medica, The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai,, 201203, China
| | - Nan Zou
- Institute of Chinese Materia Medica, The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai,, 201203, China
| | - Yudan Zhu
- Institute of Chinese Materia Medica, The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai,, 201203, China
| | - Hailian Shi
- Institute of Chinese Materia Medica, The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai,, 201203, China
| | - Xuemei Cheng
- Institute of Chinese Materia Medica, The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai,, 201203, China.
- Shanghai R&D Center for Standardization of Chinese Medicines, 199 Guoshoujing Road, Shanghai,, 201210, China.
| | - Changhong Wang
- Institute of Chinese Materia Medica, The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai,, 201203, China.
- Shanghai R&D Center for Standardization of Chinese Medicines, 199 Guoshoujing Road, Shanghai,, 201210, China.
| |
Collapse
|
10
|
Tong J, Yao X, Zeng H, Zhou G, Chen Y, Ma B, Wang Y. Hepatoprotective activity of flavonoids from Cichorium glandulosum seeds in vitro and in vivo carbon tetrachloride-induced hepatotoxicity. JOURNAL OF ETHNOPHARMACOLOGY 2015; 174:355-63. [PMID: 26320690 DOI: 10.1016/j.jep.2015.08.045] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Revised: 06/24/2015] [Accepted: 08/26/2015] [Indexed: 06/04/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Cichorium glandulosum Boiss. et Huet was used historically in Uyghur folk medicine. Its roots, seeds, and aerial parts are extensively used by Uyghur residents in Xinjiang to eliminate savda typhoid, dredge and cure obstructive jaundice variety liver disorders. AIM OF THE STUDY To evaluate the hepatoprotective activity of total flavonoids (TFs) obtained from C. glandulosum seeds against carbon tetrachloride (CCl4)-induced liver damage in vitro and in vivo. To investigate the mechanisms of hepatoprotective effects for TFs. MATERIALS AND METHODS The dried seeds of C. glandulosum were extracted with 70% aqueous ethanol, and the extract was chromatographed with D101 macroporous resin. In vitro the antioxidant capacity against lipid peroxidation (LPO) was evaluated using ferrothiocyanate, thiobarbituric acid, β-carotene bleaching, and LPO inhibition assay. The cytotoxicity and hepatoprotective activity of TFs were evaluated in human liver hepatoma cells (HepG2). MTT assay, hepatic injury markers aspartate aminotransferase (AST), alanine aminotransaminase (ALT), lactate dehydrogenase (LDH) leakage, malondialdehyde (MDA), and glutathione (GSH) were performed. In vivo the hepatoprotective activity of TFs against CCl4-induced acute liver injury was evaluated in rats. A series of biochemical and antioxidant parameter levels were measured in liver homogenate. The suppressive effect on pancreatic lipase activity was determined. RESULTS Results indicated that TFs showed antioxidant capacity against lipid peroxidation (LPO). Administrating CCl4 (1%, v/v) caused a significant decrease in HepG2 viability. Treatment with TFs at doses (62.5, 125, and 250 μg/ml) could significantly ameliorate the cytotoxicity and decline the levels of AST, ALT, and LDH induced by CCl4. The markers including MDA and GSH, which were close to oxidative damage, were restored. Oral treatment with TFs in vivo at doses of 100, 200, and 400 mg/kg significantly reduced the levels of AST, ALT, alkaline phosphatase (ALP), total bilirubin (TB), and thiobarbituric acid reactive substances (TBARs) in the serum compared with CCl4-induced acute liver injury in rats. TFs showed dose-dependent suppressive effects on pancreatic lipase activity, and the IC50 was 1.318 ± 0.164 mg/ml. CONCLUSION TFs from C. glandulosum seeds demonstrated significant hepatoprotection against CCl4-induced hepatotoxicity. TFs exhibited significant suppression of LPO and pancreatic lipase capacity, which may be the mechanisms of hepatoprotective effects against CCl4. Our results contribute towards validation of the traditional use of C. glandulosum seeds in the treatment of liver disorders.
Collapse
Affiliation(s)
- Jing Tong
- Institute of TCM & Natural Products, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, PR China
| | - Xincheng Yao
- Institute of TCM & Natural Products, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, PR China; College of Pharmacy, Shihezi University, Xinjiang Uyghur Autonomous Region, Shihezi 832000, PR China
| | - Hong Zeng
- Institute of TCM & Natural Products, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, PR China
| | - Gao Zhou
- Institute of TCM & Natural Products, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, PR China
| | - Yuxin Chen
- Institute of TCM & Natural Products, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, PR China
| | - Bingxin Ma
- Institute of TCM & Natural Products, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, PR China
| | - Youwei Wang
- Institute of TCM & Natural Products, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, PR China.
| |
Collapse
|